COMUNICADO: DIFICLIR[TM], el estándar de atención más rentable para la infección por Clostridium Difficile (y 2)

2. Heimann SM et al. Pharmacoeconomical Decision-Tree Analysis of Clostridium difficile-associated Diarrhea in Patients with Cancer Treated with Fidaxomicin or Vancomycin. Presented at ICAAC 2014.

3. Chopra T, et al. Clostridium difficile Infection in Cancer Patients and Hematopoietic Stem Cell Transplant Recipients. Expert Rev Anti Infect Ther. 2010;8(10):1113-1119.

4. Cornely OA et al. Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. J Clin Oncol 2013;31: 2493-9.

5. Heimann SM et al. Clostridium Difficile Associated Diarrhea: A Comprehensive Cost-of-Illness Analysis of Inpatient Cases. PO789 Presentado en ECCMID 2014.

6. Planche T, et al. Cost-effectiveness of fidaxomicin as first-line treatment for Clostridium difficile infection. Presentación oral O256 en ECCMID 2014.

7. Cornely OA, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Diseases. 2012:12;281-289.

8. Astellas Data on File DIF14036UK.

9. Bradshaw, D. et al. Physician perceptions of the burden of Clostridium difficile infection in Europe and the impact of recurrence. Presentado en ICAAC 2014.

10. Davies KA, et al. Second report from the EUropean, multi-centre, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID) PO753. Presentado en ECCMID 2014.

11. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.

12. Oake N, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010;170:1804-10.

13. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16.

14. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205.

15. Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Micro Infect. 2008;14(Suppl 7):S103-4.

16. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.

17. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932-1940.

18. Poutanen SM, et al. Clostridium difficile-associated diarrhoea in adults. CMAJ. 2004;171:51-8.

19. Kelly CP, et al. Clostridium difficile infection. Ann Rev Med. 1998;49:375-390.

20. Crobach MJ, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Micro Infect. 2009;15:1053-1066.

21. Pepin J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.

22. Bauer MP, et al. European Society of Clinical Microbiology and Infectious Disease (ESCMID): treatment guidance document for Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1067-79. CONTACTO: Para más información, contacte con: Donna Wright, Ruder Finn,dwright@ruderfinn.co.uk, Tel: +44-(0)20-7438-3085; Mindy Dooa, AstellasPharma EMEA, mindy.dooa@astellas.com , Tel: +44-(0)7826-912-339